Nuohui Health (06606) rose nearly 7% again, rising more than 30% during the month. As of press release, it rose 6.62% to HK$24.95, with a turnover of HK$71.764,400.
The Zhitong Finance app learned that Novartis Health (06606) rose nearly 7% again, rising more than 30% during the month. As of press release, it rose 6.62% to HK$24.95, with a turnover of HK$71.764,400.
According to news, on November 13, Nov. 13, Nov. Health announced that the omni-channel sales of Double 11 e-commerce in 2023 will exceed 80 million yuan, an increase of more than 30% over 2022 Double 11. Meanwhile, as of November 10, Chang Weiqing's cumulative inspection volume in 2023 reached 880,000, and confirmed revenue exceeded 1 billion yuan. The company has completed a cash repayment of nearly 1 billion yuan.
It is worth noting that Novartis Health recently signed a strategic cooperation with Takeda China at the Shanghai Expo to jointly create a full-course management solution for Helicobacter pylori patients in China. Through innovative cooperation spanning the fields of diagnosis and treatment, Novartis Health collaborated to create a full course management service for Helicobacter pylori infected in China, from screening, diagnosis, treatment to follow-up.